Lillian Siu
Princess Margaret Cancer Centre · University Health Network, Toronto · Princess Margaret Hospital, Canada
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
43
all conditions, ClinicalTrials.gov
NIH grants tied to them
2
NIH RePORTER
Trial papers
182
PubMed author-name match
Trials
Studies that name Lillian Siu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:07 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07524114 · Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)University Health Network, Toronto · recruiting · Breast Cancer, Lung Cancer, Melanoma · principal investigator
- Ph2NCT07408063 · A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)University Health Network, Toronto · recruiting · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT05414032 · Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCCUniversity Health Network, Toronto · recruiting · Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) · principal investigator
- N/ANCT05403177 · Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)University Health Network, Toronto · recruiting · Breast Cancer, Colorectal Cancer, Pancreas Cancer · principal investigator
- N/ANCT05196087 · Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)University Health Network, Toronto · recruiting · Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor · principal investigator
- N/ANCT04606940 · Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)University Health Network, Toronto · completed · Head and Neck Cancer, Advanced Cancer, Metastatic Cancer · principal investigator
- N/ANCT04599309 · Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell CarcinomaUniversity Health Network, Toronto · active not recruiting · Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer · principal investigator
- Ph2NCT04262388 · A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationUniversity Health Network, Toronto · withdrawn · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck · principal investigator
- N/ANCT04243720 · Immune Resistance Interrogation StudyUniversity Health Network, Toronto · recruiting · Cancer, Solid Tumor, Metastatic Cancer · principal investigator
- Ph2NCT03851614 · Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsUniversity Health Network, Toronto · active not recruiting · Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma · principal investigator
- N/ANCT03759730 · Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell CarcinomaUniversity Health Network, Toronto · completed · Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma · principal investigator
- N/ANCT03702309 · Liquid Biopsy Evaluation and Repository Development at Princess MargaretUniversity Health Network, Toronto · recruiting · Cancer, Breast Cancer, Lung Cancer · principal investigator
- Ph2/Ph3NCT03686202 · Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy PatientsUniversity Health Network, Toronto · active not recruiting · All Solid Tumors · principal investigator
- Early Ph1NCT03575598 · Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyUniversity Health Network, Toronto · completed · Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth, Squamous Cell Carcinoma of the Oral Cavity · principal investigator
- Ph1NCT03489343 · Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasSymphogen A/S · completed · Metastatic Cancer, Solid Tumor, Lymphoma · principal investigator
- Ph1NCT03489369 · Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasSymphogen A/S · completed · Metastatic Cancer, Solid Tumor, Lymphoma · principal investigator
- N/ANCT03364621 · Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer TherapyUniversity Health Network, Toronto · active not recruiting · Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases · principal investigator
- Ph1NCT03311412 · Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or LymphomasSymphogen A/S · completed · Metastatic Cancer, Solid Tumor, Lymphoma · principal investigator
- Ph2NCT03297606 · Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Canadian Cancer Trials Group · recruiting · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors · study chair
- Ph1/Ph2NCT03058289 · A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6Intensity Therapeutics, Inc. · completed · Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma · study chair
- Ph1NCT02993991 · Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityUniversity Health Network, Toronto · withdrawn · Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth, Resectable Squamous Cell Carcinoma of Oral Cavity · principal investigator
- N/ANCT02906943 · Ontario-wide Cancer TArgeted Nucleic Acid EvaluationUniversity Health Network, Toronto · recruiting · Breast Cancer, Lung Cancer, Colorectal Cancer · principal investigator
- Ph2NCT02811497 · Study of Azacitidine and Durvalumab in Advanced Solid TumorsUniversity Health Network, Toronto · completed · Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and HER2 Negative Breast Cancer · principal investigator
- N/ANCT02724488 · Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesUniversity Health Network, Toronto · completed · Head and Neck Cancer, Melanoma · principal investigator
- Ph2NCT02644369 · Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsUniversity Health Network, Toronto · active not recruiting · Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer · principal investigator
- N/ANCT02586844 · Prospective Comprehensive Molecular Profiling In Neuroendocrine TumorsUniversity Health Network, Toronto · completed · Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors · principal investigator
- Ph2NCT02319044 · Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and NeckAstraZeneca · completed · Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck · principal investigator
- N/ANCT02100371 · Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus SyndromeUniversity Health Network, Toronto · completed · Basal Cell Nevus Syndrome · principal investigator
- Ph1NCT01884285 · AZD8186 First Time In Patient Ascending Dose StudyAstraZeneca · completed · Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC · principal investigator
- Ph1NCT01737008 · Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and NeckUniversity Health Network, Toronto · completed · Squamous Cell Carcinoma of the Head and Neck · principal investigator
- N/ANCT01703585 · Feasibility Study of Genomic Profiling Methods and Timing in Tumor SamplesUniversity Health Network, Toronto · completed · Colorectal Cancer, Breast Cancer, Gynecological Cancer · principal investigator
- N/ANCT01543841 · Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in BloodUniversity Health Network, Toronto · completed · Advanced Cancer, Healthy · principal investigator
- N/ANCT01484847 · A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell CarcinomaUniversity Health Network, Toronto · completed · Head and Neck Squamous Cell Carcinoma · principal investigator
- N/ANCT01345513 · Feasibility Clinical Study of Targeted and Genome-Wide SequencingUniversity Health Network, Toronto · completed · Solid Tumors · principal investigator
- Ph1/Ph2NCT01116843 · Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative TreatmentUniversity Health Network, Toronto · completed · Oral Cavity Cancer · principal investigator
- Ph1NCT01096355 · Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid MalignanciesNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT00731380 · A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck CancerUniversity Health Network, Toronto · completed · Head and Neck Cancer · principal investigator
- Ph1NCT00706316 · Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal CancerUniversity Health Network, Toronto · completed · Nasopharyngeal Cancer · principal investigator
- Ph2NCT00605566 · Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine TumorsUniversity Health Network, Toronto · completed · Neuroendocrine Tumors · principal investigator
- Ph2NCT00603915 · A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal CancerUniversity Health Network, Toronto · completed · Nasopharyngeal Cancer · principal investigator
- Ph1NCT00369252 · Phase I Study of Nimotuzumab in Solid TumoursYM BioSciences · completed · Advanced and/or Metastatic Solid Tumours · principal investigator
- Ph2NCT00095563 · Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersNational Cancer Institute (NCI) · completed · High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma · principal investigator
- Ph2NCT00093782 · Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaNational Cancer Institute (NCI) · completed · Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2014 to 2026 · $1,770,712 awarded in 2026Same name and institution; not confirmed by an ID
- Princess Margaret Hospital Phase I ConsortiumU01CA132123 · NCI · UNIVERSITY HEALTH NETWORK · fiscal years 2008 to 2013 · $607,562 awarded in 2013Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:07 UTC. The ranking covers the 200 most relevant of 182 PubMed records, and a shared surname and initials can bring in a namesake. All 182 on PubMed
- Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.J Clin Oncol · 2001862 citationsRCR 17.8
- 650 citationsRCR 13.7
- Dose escalation methods in phase I cancer clinical trials.J Natl Cancer Inst · 2009645 citationsRCR 13.9
- 365 citationsRCR 9.3
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.Br J Cancer · 2006265 citationsRCR 6.2
- Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma.J Natl Cancer Inst · 2010260 citationsRCR 7.3
- 258 citationsRCR 8.9
- Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.J Clin Oncol · 2005251 citationsRCR 6.1
- 248 citationsRCR 5.0
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.J Clin Oncol · 2018246 citationsRCR 7.6